Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05120661
Other study ID # NL78737.091.21
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 9, 2021
Est. completion date July 1, 2022

Study information

Verified date October 2023
Source Wageningen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It has been shown that person-specific factors, such as the fecal microbiome, influenced postprandial glycemia. The small intestine is the site of nutrient digestion and absorption. The small intestine microbiota is amendable by dietary changes, and plays a key role in host adaptability to dietary variations. The role of the human small intestine microbiota in regulating postprandial glycemic responses towards food products will be investigated. First a screening will take place with to choose the test products that elicit most differential glucose responses and to select subjects with differential postprandial response to the same food product. The study will be a 6-day randomized cross-over trial with two test days. Four test (food) products, each containing 50 gram carbohydrates, and an oral glucose tolerance test will be provided to participants. Twenty men or women (BMI≥25 kg/m2, 40-75 years old) will be included. The main study parameters/endpoints are the food product-induced plasma glucose responses (iAUC) and the small intestine microbiota.


Description:

Rationale: It has been shown that person-specific factors, such as the fecal microbiome, influenced postprandial glycemia. The small intestine is the site of nutrient digestion and absorption. The small intestine microbiota is amendable by dietary changes, and plays a key role in host adaptability to dietary variations. Differences in small intestine microbiota are hypothesized to be key in explaining the interpersonal differences in glycemic responses. Objective: To investigate the role of the human small intestine microbiota in regulating postprandial glycemic responses towards food products. Study design: The subjects will wear a continuous glucose monitor during the screening and the study. First a screening (14 days in total) will take place with to choose the test products (2 out of 4) that elicit most differential glucose responses and to select subjects with differential postprandial response to the same food product. Also an OGTT will be performed. The study will be a randomized cross-over trial with two test days (length of trial is 6 days in total). During the trial, the subjects will be intubated with a naso-jejunum catheter. Study population: Twenty men or women (BMI≥25 kg/m2, 40-75 years old). Intervention (if applicable): Four test (food) products, each containing 50 gram carbohydrates, and an oral glucose tolerance test. Main study parameters/endpoints: test (food) product-induced plasma glucose responses (iAUC), small intestine microbiota.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 1, 2022
Est. primary completion date July 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Males and females - BMI=25 kg/m2 - Age 40-75 years - Signed informed consent Exclusion Criteria: - Having a history of medical or surgical events that may either put the subject at risk because of participation in the study, or influence the results of the study, including diabetes type 1, a swallowing disorder, gastrointestinal or liver disease, renal failure, cancer, nose/throat diseases, gastric bypass surgery, use of anticoagulants; - Having a bleeding/coagulation disorder, including hemophilia, Von Willebrand disease, Bernard-Soulier, Glanzmann thrombasthenia or thrombocytopenia; - Use of antibiotics within 2 months of starting the study or planned during the study; - Use of medication that could influence the study results, such as diabetes treatment; - Use of pro- and prebiotic supplements; - Sensitive to medical skin adhesives; - Having an allergy or intolerance towards compounds in the test products; - Follows a vegan diet; - Excessive alcohol consumption (on average >21 glasses/week for men and >14 glasses/week for women); - Currently a research subject in another clinical trial; - Having blood vessels that are too difficult for inserting a cannula/blood drawing' - Having a hemoglobin level <8.5 mmol/l (men) or <7.5 mmol/l (women); - Being a blood donor during the duration of the study; - Not having a General Practitioner (GP); - Being an employee of Wageningen University, division Human Nutrition and Health.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
food product
a food product containing 50 gram carbohydrates

Locations

Country Name City State
Netherlands Wageningen University Wageningen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Wageningen University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary postprandial glucose response (iAUC) per test product iAUC glucose 0-120 minutes
Primary small intestine microbiome the relative composition (%) and the functional capacity (%) of the small intestine microbiota at baseline
Secondary macronutrients in the small intestinal aspirates amounts of carbohydrates, proteins, fats 0-240 minutes
Secondary presence and production of (bacterial) degradation products in the small intestinal aspirates concentrations of organic acids and short-chain fatty acids 0-240 minutes
Secondary digestive enzymes in the small intestinal aspirates concentrations of amylase 0-240 minutes
Secondary non-absorbable marker in the small intestinal aspirates peg-4000 concentrations 0-240 minutes
Secondary blood HbA1c concentrations of HbA1c 0-240 minutes
Secondary blood glucose concentrations glucose (e.g. GLP-1, PYY) 0-240 minutes
Secondary blood insulin concentrations of insulin 0-240 minutes
Secondary blood glucagon concentrations of glucagon 0-240 minutes
Secondary blood total triglycerides concentrations of triglycerides 0-240 minutes
Secondary blood total free fatty acids concentrations of free fatty acids 0-240 minutes
Secondary plasma gut hormones concentrations of gut hormones (e.g. GLP-1, PYY) 0-240 minutes
Secondary breath 13C-lactosyl ureide concentrations of 13C-lactosyl ureide 0-240 minutes
Secondary breath hydrogen concentrations of hydrogen (ppm) 0-240 minutes
Secondary breath methane concentrations of methane (ppm) 0-240 minutes
Secondary Oral microbiome composition microbiota relative composition (%) baseline
Secondary Salivary a-amylase concentrations of a-amylase 0-240 minutes
Secondary Fecal microbiota composition microbiota relative composition (%) baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2